Checkpoint inhibitor therapy is a form of cancer immunotherapy targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA4), programmed cell death-1 (PD-1), and programmed cell death-ligand 1 (PD-L1) to restore immune system function (1). Here, PDCD1 is linked to cancer.